FDA Approves Sanofi's Nasacort Allergy 24HR Nasal Spray as OTC Treatment

Sanofi SNY announced today that the U.S. Food and Drug Administration (FDA) approved Nasacort® Allergy 24HR nasal spray as an over-the-counter (OTC) treatment for seasonal and year-round nasal allergies in adults and children 2 years of age and older. Nasacort is the first and only medicine in its class to be available without a prescription and will be marketed by Sanofi's consumer healthcare division, Chattem, Inc. "We believe there is significant value in making certain types of medicines, like Nasacort, directly available to consumers," said Anne Whitaker, President, North America Pharmaceuticals, Sanofi US.  "Allergy sufferers will benefit from having an additional treatment option and it's a strong addition to our existing consumer health portfolio." Up to 60 million Americans suffer from seasonal and year-round nasal allergies annually.  This can have a major disruption to the quality of life of both adults and children, interfering with sleep, outdoor activities, and for children their performance at school. Nasacort and nasal sprays in the same medication class are considered the most effective treatment for hay fever and other upper respiratory See full press release